A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo Controlled First-in-human Trial To Evaluate The Safety,Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06751979 After Oral Administration Of Single And Multiple Ascending Doses To Healthy Adult And Elderly Subjects
Phase of Trial: Phase I
Latest Information Update: 22 Jul 2016
At a glance
- Drugs PF 6751979 (Primary) ; PF 6751979 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 18 Jul 2016 Status changed from active, no longer recruiting to completed.
- 11 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 03 Jun 2016 Planned End Date changed from 1 Aug 2016 to 1 Jul 2016.